Abstract:Background: Despite the promising potential of neoadjuvant immune checkpoint blockade (ICB) in ESCC, postoperative recurrence remains a critical challenge. Besides pathological response, there remains no biomarkers for recurrence risk prediction after neoadjuvant ICB. Recent studies have highlighted a strong association between ICB efficacy and tumor immune microenvironment (TIME). Thus, we sought to investigate the TIME features in surgically resected tumors following neoadjuvant ICB from patients with ESCC to develop a potential way for recurrence risk prediction. Methods: This is a side study of a phase 2 NICE trial (ChiCTR1900026240) of 51 patients with resectable locally advanced ESCC who received neoadjuvant ICB plus chemotherapy followed by surgery from 2019 to 2020. TIME features of surgically resected tumors after neoadjuvant therapy were assessed by multiplex immunohistochemistry (mIHC) for immune markers (CD8, PD-L1, CD45RO, PD-1, Pan-CK, CD4, FoxP3, CD68, CD163). We first analyzed TIME features in tumors evaluated as pathological complete response (pCR) and major pathological response (MPR). Then, we divided 51 patients into a training and validation set; and machine learning was applied to identify a list of TIME features that predict recurrence-free survival (RFS) and to develop a TIME-based signature (TIS) on neoadjuvant ICB prognosis. Results: Fifty-one patients from NICE trial were used for primary analysis. A higher positive rate of CD8+ cells, CD163−CD68+ macrophages and CD8+CD45RO+ cells was observed in patients with pCR. Similarly, MPR patients exhibited a higher positive rate of CD8+ cells and CD8+CD45RO+ cells. Regarding RFS prediction, machine learning selection of TIS were identified: CD8+PD1−(cytotoxic T cells), CD4+Foxp3+ (Treg), CD8+CD45RO+ (memory T cells), and M1 macrophages (CD163−CD68+) exhibited significant predictive value. Stratifying patients into low- and high-risk groups using TIS for RFS revealed a prolonged prolonged RFS in the low-risk group (p<0.001; HR: 0.08, 95% CI [0.03-0.25]). Notably, when applying TIS to pCR patients, we identified a subset of high-risk pCR patients (median RFS = 8.9 months, 1- year RFS=32%) relapsed earlier than low-risk pCR patients (median RFS = not reached, 1-year RFS=100%, p<0.001). Multivariable Cox regression analysis demonstrated that TIS was an independent predictor for RFS as well as overall survival (both p<0.001). Further independent validation (ICB and non-ICB cohort) of TIS is ongoing. Conclusion: The establishment of a risk prediction model based on TIME demonstrated the potential to enhance postoperative monitoring management for ESCC patients who underwent surgery after neoadjuvant ICB. Our study provides insights into development of optimal post-immunotherapy management strategy. Citation Format: Zhichao Liu, Boyao Yu, Yuxin Yang, Cong Qi, Chang Yuan, Yang Yang, Jinzhi Wei, Sidong Chen, Yang Wang, Zhigang Li. Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7646.

Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer

Comprehensive Analysis of Tumor Immune Microenvironment Characteristics for the Prognostic Prediction and Immunotherapy of Oral Squamous Cell Carcinoma

Immune Microenvironment-Related Genes Contribute to Clinical Prognosis in Patients with Triple-Negative Breast Cancer

Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence

Tumor Microenvironment Derived Signature Predicting Relapse-Free Survival in I-III Cancer and Preliminary Experiment Verification.

The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer

Abstract 7646: Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk

Clinical analysis of 21-gene recurrence score assay applied in early-stage breast cancer patients

Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer

Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer

Improving ovarian cancer treatment decision using a novel risk predictive tool

Constructing Tumor Immune Microenvironment and Identifying the Immune-Related Prognostic Signatures in Colorectal Cancer Using Multi-omics Data

Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients

Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures

An Assessment of Prognostic Immunity Markers in Breast Cancer

Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial

CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: a comprehensive analysis based on TCGA database